EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations

Junxiang Wang, Kaiyi Li, Yuan Wang, Zhengfang Lin, Weidong Li, Jinpeng Cao, Xinyue Mei, Rui Wei, Jinglu Yang, Xiaobing Zhai, Deyi Huang, Kaiwen Zhou und 2 weitere

mBio · 2024

DOI: 10.1128/mbio.01429-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Junxiang Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health,…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Lymphocyte Activation, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited knowledge is available on the differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibody breadth and T cell differentiation among different COVID-19 sequential vaccination strategies. In this study, we compared the immunogenicity of the third different dose of COVID-19 vaccines, such as mRNA (I-I-M), adenoviral vector (I-I-A), and recombinant protein (I-I-R) vaccines, in terms of the magnitude and breadth of antibody response and differentiation of SARS-CoV-2-specific T and B cells. These studies were performed in the same clinical trial, and the samples were assessed in the same laboratory. IGHV1-69, IGHV3-9, and IGHV4-34 were the dominant B cell receptor (BCR) usages of the I-I-M, I-I-A, and I-I-R groups, respectively; the RBD + B cell activation capacities were comparable. Additionally, the I-I-R group was characterized by higher numbers of regulatory T cells, circulating T follicular helper cells (cTFH) – cTFH1 (CXRC3 + CCR6 - ), cTFH1-17 (CXRC3 + CCR6 + ), cTFH17 (CXRC3 - CCR6 + ), and cTFH-CM (CD45RA - CCR7 + ), and lower SMNE + T cell proliferative capacity than the other two groups, whereas I-I-A showed a higher proportion and number of virus-specific CD4 + T cells than I-I-R, as determined in ex vivo experiments. Our data confirmed different SARS-CoV-2-specific antibody profiles among the three different vaccination strategies and also provided insights regarding BCR usage and T/B cell activation and differentiation, which will guide a better selection of vaccination strategies in the future. IMPORTANCE Using the same laboratory test to avoid unnecessary interference due to cohort ethnicity, and experimental and statistical errors, we have compared the T/B cell immune response in the same cohort sequential vaccinated by different types of COVID-19 vaccine. We found that different sequential vaccinations can induce different dominant BCR usage with no significant neutralizing titers and RBD + B-cell phenotype. Recombinant protein vaccine can induce higher numbers of regulatory T cells, circulating TFH (CTFH)1, CTFH17, and CTFH-CM, and lower SMNE + T-cell proliferative capacity than the other two groups, whereas I-I-A showed higher proportion and number of virus-specific CD4 + T cells than I-I-R. Overall, our study provides a deep insight about the source of differences in immune protection of different types of COVID-19 vaccines, which further improves our understanding of the mechanisms underlying the immune response to SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19Lymphocyte ActivationSARS-CoV-2B-LymphocytesAntibodies, ViralReceptors, Antigen, B-CellHumansVaccinationT-LymphocytesFemaleMaleAdultMiddle AgedAntibodies, Neutralizing

Stichwörter der Autor:innen

BCR usageSARS-CoV-2T cellsvaccine

Substanzen

COVID-19 VaccinesAntibodies, ViralReceptors, Antigen, B-CellAntibodies, Neutralizing

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangz…
  • Department of Clinical Laboratory, Dongguan Maternal and Child Health Care Hospital, Dongguan, China.
  • Guangzhou National Laboratory, Bioland, Guangzhou, Guangdong, China.
  • West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
  • Shenzhen Hetao Institute, Guangzhou National Laboratory, Shenzhen, Guangdong, China.

ORCID-Profile: Zhongfang Wang

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)

Zitieren

APA

Wang, J., Li, K., Wang, Y., Lin, Z., Li, W., Cao, J., Mei, X., Wei, R., Yang, J., Zhai, X., Huang, D., Zhou, K., Liang, X., & Wang, Z. (2024). Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations. mBio. https://doi.org/10.1128/mbio.01429-24

Vancouver

Wang J, Li K, Wang Y, Lin Z, Li W, Cao J, et al. Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations. mBio. 2024. doi:10.1128/mbio.01429-24

BibTeX
@article{Wang2024,
  author = {Wang, Junxiang and Li, Kaiyi and Wang, Yuan and Lin, Zhengfang and Li, Weidong and Cao, Jinpeng and Mei, Xinyue and Wei, Rui and Yang, Jinglu and Zhai, Xiaobing and Huang, Deyi and Zhou, Kaiwen and Liang, Xinyue and Wang, Zhongfang},
  title = {Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.01429-24}
}
Kostenlos starten →